The global depression drugs market size reached US$ 18.6 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.2% during 2023-2032.
Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.
According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.
This latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.
2. What has been the impact of COVID-19 on the global depression drugs market?
3. What is the expected growth rate of the global depression drugs market?
4. What are the key factors driving the global depression drugs market?
5. What is the breakup of the global depression drugs market based on the disorder type?
6. What is the breakup of the global depression drugs market based on the distribution channel?
7. What are the key regions in the global depression drugs market?
8. Who are the key companies/players in the global depression drugs market?
Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.
According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.
This latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts at the global and regional level from 2024-2032. The report has categorized the market based on drug class, disorder type, drug type and distribution channel.Breakup by Drug Class:
- Atypical Antipsychotics
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Central Nervous System (CNS) Stimulants
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Others
Breakup by Disorder Type:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
Breakup by Drug Type:
- Generic Drugs
- Branded Drugs
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Breakup by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Competitive Landscape:
The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.Key Questions Answered in This Report
1. What is the size of the global depression drugs market?2. What has been the impact of COVID-19 on the global depression drugs market?
3. What is the expected growth rate of the global depression drugs market?
4. What are the key factors driving the global depression drugs market?
5. What is the breakup of the global depression drugs market based on the disorder type?
6. What is the breakup of the global depression drugs market based on the distribution channel?
7. What are the key regions in the global depression drugs market?
8. Who are the key companies/players in the global depression drugs market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Depression Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Disorder Type
8 Market Breakup by Drug Type
9 Market Breakup by Distribution Channel
10 Market Breakup by Region
11 SWOT Analysis
13 Porter’s Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Otsuka Pharmaceutical
- Pfizer
- Eli Lilly and Company
- AstraZeneca
- Novartis
- Bristol-Myers Squibb
- GlaxoSmithKline
- Takeda Pharmaceutical Company
- Allergan
- Johnson & Johnson
- Zhejiang NHU Company Ltd and Sebela Pharmaceuticals
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 148 |
| Published | March 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 18.6 Billion |
| Forecasted Market Value ( USD | $ 24.6 Billion |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
